Li Rebekah Feng1, Jennifer J Barb2, Jeniece Regan3, Leorey N Saligan1. 1. National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA. 2. Clinical Center, National Institutes of Health, Bethesda, MD, USA. 3. The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Abstract
BACKGROUND: Metabolomics is the newest -omics methodology and allows for a functional snapshot of the biochemical activity and cellular state. The goal of this study is to characterize metabolomic profiles associated with cancer-related fatigue, a debilitating symptom commonly reported by oncology patients. METHODS: Untargeted ultrahigh performance liquid chromatography/mass spectrometry metabolomics approach was used to identify metabolites in plasma samples collected from a total of 197 participants with or without cancer. Partial least squares-discriminant analysis (PLS-DA) was used to identify discriminant metabolite features, and diagnostic performance of selected classifiers was quantified using area under the receiver operating characteristics (AUROC) curve analysis. Pathway enrichment analysis was performed using Fisher's exact test and the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway database. FINDINGS: The global metabolomics approach yielded a total of 1120 compounds of known identity. Significant metabolic pathways unique to fatigued cancer versus control groups included sphingolipid metabolism, histidine metabolism, and cysteine and methionine metabolism. Significant pathways unique to non-fatigued cancer versus control groups included inositol phosphate metabolism, primary bile acid biosynthesis, ascorbate and aldarate metabolism, starch and sucrose metabolism, and pentose and glucuronate interconversions. Pathways shared between the two comparisons included caffeine metabolism, tyrosine metabolism, steroid hormone biosynthesis, sulfur metabolism, and phenylalanine metabolism. CONCLUSIONS: We found significant metabolomic profile differences associated with cancer-related fatigue. By comparing metabolic signatures unique to fatigued cancer patients with metabolites associated with, but not unique to, fatigued cancer individuals (overlap pathways) and metabolites associated with cancer but not fatigue, we provided a broad view of the metabolic phenotype of cancer-related fatigue.
BACKGROUND: Metabolomics is the newest -omics methodology and allows for a functional snapshot of the biochemical activity and cellular state. The goal of this study is to characterize metabolomic profiles associated with cancer-related fatigue, a debilitating symptom commonly reported by oncology patients. METHODS: Untargeted ultrahigh performance liquid chromatography/mass spectrometry metabolomics approach was used to identify metabolites in plasma samples collected from a total of 197 participants with or without cancer. Partial least squares-discriminant analysis (PLS-DA) was used to identify discriminant metabolite features, and diagnostic performance of selected classifiers was quantified using area under the receiver operating characteristics (AUROC) curve analysis. Pathway enrichment analysis was performed using Fisher's exact test and the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway database. FINDINGS: The global metabolomics approach yielded a total of 1120 compounds of known identity. Significant metabolic pathways unique to fatigued cancer versus control groups included sphingolipid metabolism, histidine metabolism, and cysteine and methionine metabolism. Significant pathways unique to non-fatigued cancer versus control groups included inositol phosphate metabolism, primary bile acid biosynthesis, ascorbate and aldarate metabolism, starch and sucrose metabolism, and pentose and glucuronate interconversions. Pathways shared between the two comparisons included caffeine metabolism, tyrosine metabolism, steroid hormone biosynthesis, sulfur metabolism, and phenylalanine metabolism. CONCLUSIONS: We found significant metabolomic profile differences associated with cancer-related fatigue. By comparing metabolic signatures unique to fatigued cancerpatients with metabolites associated with, but not unique to, fatigued cancer individuals (overlap pathways) and metabolites associated with cancer but not fatigue, we provided a broad view of the metabolic phenotype of cancer-related fatigue.
Authors: Li Rebekah Feng; Brian S Wolff; Nada Lukkahatai; Alexandra Espina; Leorey N Saligan Journal: Cancer Nurs Date: 2017 May/Jun Impact factor: 2.592
Authors: Erikka Loftfield; Marilyn C Cornelis; Neil Caporaso; Kai Yu; Rashmi Sinha; Neal Freedman Journal: JAMA Intern Med Date: 2018-08-01 Impact factor: 21.873
Authors: Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: Robert K Naviaux; Jane C Naviaux; Kefeng Li; Lin Wang; Jonathan M Monk; A Taylor Bright; Hayley J Koslik; Janis B Ritchie; Beatrice A Golomb Journal: PLoS One Date: 2019-07-26 Impact factor: 3.240
Authors: Daniel I Benjamin; Sharon M Louie; Melinda M Mulvihill; Rebecca A Kohnz; Daniel S Li; Lauryn G Chan; Antonio Sorrentino; Sourav Bandyopadhyay; Alyssa Cozzo; Anayo Ohiri; Andrei Goga; Shu-Wing Ng; Daniel K Nomura Journal: ACS Chem Biol Date: 2014-04-28 Impact factor: 5.100
Authors: Sylvia L Crowder; Mary C Playdon; Lisa M Gudenkauf; Jennifer Ose; Biljana Gigic; Leigh Greathouse; Anita R Peoples; Alix G Sleight; Heather S L Jim; Jane C Figueiredo Journal: Nutrients Date: 2022-04-02 Impact factor: 6.706
Authors: Anne Kerstin Thomann; Torsten Wüstenberg; Jakob Wirbel; Laura-Louise Knoedler; Philipp Arthur Thomann; Georg Zeller; Matthias Philip Ebert; Stefanie Lis; Wolfgang Reindl Journal: BMC Med Date: 2022-10-17 Impact factor: 11.150